Background: The aim of this study was to determine whether the combined use of the C-reactive protein (CRP) level and neutrophil-lymphocyte ratio (NLR) before treatment predicts disease-specific survival in adult patients with soft tissue sarcoma (STS).
Methods: We retrospectively reviewed 142 patients who presented with STS between 1995 and 2010.
Results: The NLR varied from 0.54 to 7.59. An elevated CRP level was observed in 36 patients before treatment. The patients with both an elevated CRP level and high NLR had a poorer disease-specific survival (46% at 5 years) than the patients with both a normal CRP level and low NLR (87% at 5 years) (P = 0.0005). The patients with both an elevated CRP level and high NLR also had a poorer disease-specific survival than the patients with either an elevated CRP level or high NLR (75.6% at five years) (P = 0.03). There were no significantly prognostic differences between the patients with a normal CRP level and low NLR and those with either an elevated CRP level or high NLR (P = 0.18). A multivariate analysis also showed the preoperative NLR and CRP level to be independent predictors of survival.
Conclusions: We recommend the routine measurement of these markers to identify patients with a greater risk of death.
Keywords: C-reactive protein; Neutrophil-lymphocyte ratio; biomarker; soft tissue sarcoma; survival.
© 2013 Wiley Periodicals, Inc.